- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ultrasound contrast war continues
The battle between ultrasound contrast companies over patents continues to rage on. Molecular Biosystems has announced that it received notice from the U.S. Patent Office (PTO) that the firm's petitions seeking reexamination of two patents held by rival
The battle between ultrasound contrast companies over patents continues to rage on. Molecular Biosystems has announced that it received notice from the U.S. Patent Office (PTO) that the firm's petitions seeking reexamination of two patents held by rival ImaRx Pharmaceuticals have been granted. The PTO will subject all claims of the ImaRx patents to reconsideration as to whether any of those claims are patentable, according to San Diego-based MBI.
The PTO said that it will review certain prior-art references brought to the PTO's attention in MBI's reexamination petitions, according to MBI. The key prior-art references include several that ImaRx did not disclose to the PTO during prosecution of the Tucson, AZ-based company's patent applications, MBI said. The PTO orders state that specific references raise substantial new questions concerning the patentability of the ImaRx patent claims, according to MBI.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
